Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
Galapagos’ Acquisition of CellPoint
Simcha Therapeutics’ $40 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
Acadia Pharmaceuticals’ Collaboration Agreement with Stoke Therapeutics
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
Chroma Medicine’s $125 Million Financing
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
AbSci’s Acquisition of Totient
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
Graphite Bio’s $238 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Goodwin Procter advised Graphite Bio on the deal. Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies...
4D pharma plc’s Merger with Longevity Acquisition Corporation
Wilson Sonsini Goodrich & Rosati and Pinsent Masons advised 4D pharma plc on the deal. 4D pharma plc, a Leeds, UK-based pharmaceutical company leading the development...